Giant Cell Carcinoma

This is a rare and aggressive type of cancer that starts in the lining of glands. It's often found in the lungs or thyroid.

Condition

What people with Giant Cell Carcinoma report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Giant Cell Carcinoma

What It Is

Giant cell carcinoma is a rare and aggressive cancer made up of unusually large, abnormal-looking cancer cells, many of them containing several nuclei. It most often starts in the lung, where it is a type of non-small cell lung cancer, the broad group that includes most lung cancers. Within that group, it belongs to a small family called sarcomatoid carcinomas: cancers that begin in the cells lining the airways but look and behave partly like sarcomas, the cancers of connective tissue. Giant cell carcinoma of the lung makes up well under 1 percent of lung cancers. It tends to grow quickly and to spread early through the blood and lymph system, most often to the brain, bones, adrenal glands and liver. Many people first notice symptoms common to other lung cancers, such as a cough that won't go away, coughing up blood, chest pain, shortness of breath or weight loss, and some have no symptoms until the tumor is found on a scan. The same name is sometimes used for rare giant cell cancers of other organs, such as the thyroid or pancreas. Those are separate diseases with their own tests and treatment; this page describes the lung form.

Causes & Risk Factors

Researchers do not know exactly why giant cell carcinoma develops. Like other lung cancers, it grows from genetic changes that build up in lung cells over time. Most of these changes are acquired during life rather than inherited. Smoking is the clearest risk factor. Sarcomatoid lung cancers, including giant cell carcinoma, are seen more often in older men with a history of smoking, and tobacco exposure is thought to explain the large number of genetic changes these tumors carry. Other recognized lung cancer risks, such as radon, asbestos and other workplace exposures, likely apply as well, although they have not been studied specifically for this rare subtype. Some people who develop it have never smoked.

How It's Diagnosed

Diagnosis usually starts with imaging after symptoms appear or a scan is done for another reason. A CT scan (computed tomography, a detailed X-ray scan) typically shows a single, often large mass, frequently in the outer part of an upper lobe of the lung. A PET (positron emission tomography) scan, which shows how actively tissue uses sugar, often lights up these tumors strongly, and it helps show whether cancer has spread. No scan can tell giant cell carcinoma apart from other lung cancers, though. The diagnosis depends on a pathologist examining tumor tissue under a microscope. A needle biopsy or bronchoscopy (a thin, lighted tube passed into the airways) can show a non-small cell lung cancer with sarcomatoid or giant cell features. Because the label giant cell carcinoma applies only when the tumor is made of these cells throughout, a firm diagnosis often has to wait until the whole tumor has been removed and examined. When surgery is not possible, the biopsy result is usually enough to plan treatment. The tumor tissue is also tested in ways that directly shape treatment. PD-L1 testing measures a protein on cancer cells that helps predict whether immunotherapy may work, and many sarcomatoid lung cancers have high levels. Genetic testing of the tumor looks for changes that targeted drugs can act on, especially MET exon 14 skipping, which is more common in this family of cancers than in other lung cancers. Staging scans of the brain and body show how far the cancer has spread.

Treatment Options

Treatment depends mainly on the stage of the cancer, the results of tumor testing and a person's overall health. Because giant cell carcinoma is so rare, almost no studies look at it alone; most evidence pools it with the other sarcomatoid lung cancers, and much of it comes from case reports and retrospective studies rather than large trials. When the cancer is found early and has not spread, surgery to remove the tumor and nearby lymph nodes offers the best chance of cure, and people who can have surgery live longer on average than those who cannot. The cancer often returns after surgery, usually somewhere else in the body, so doctors may recommend chemotherapy afterward, particularly for stage II or III disease. Radiation can shrink a tumor before surgery, lower the chance of it returning at the same site, or ease pain and other symptoms, although these tumors respond to radiation less well than many lung cancers. About half of people already have cancer that has spread when they are diagnosed, so treatment with medicines throughout the body becomes the main approach. Immunotherapy drugs called immune checkpoint inhibitors, such as pembrolizumab (Keytruda), help the immune system recognize and attack the cancer. They are often given with chemotherapy, and some people with these tumors have had strong, lasting responses. They can also cause the immune system to inflame healthy organs, such as the lungs, bowel, liver or hormone glands, which is why regular blood tests and quick reporting of new symptoms are part of treatment. If tumor testing finds MET exon 14 skipping, MET inhibitors such as capmatinib (Tabrecta) or tepotinib (Tepmetko), pills approved for metastatic non-small cell lung cancer with this change, are an option, although targeted drugs tend to work less well in sarcomatoid cancers than in other lung cancers. Standard platinum-based chemotherapy is used when no target is found or alongside other drugs, but on its own it usually controls this cancer only briefly. Clinical trials are worth asking about at every stage.

What to Expect

Giant cell carcinoma is a serious diagnosis, and its outlook is generally worse than for more common non-small cell lung cancers. In large studies of sarcomatoid lung cancers, most of them found at an advanced stage, roughly 15 to 20 out of every 100 people were alive five years after diagnosis. Those figures describe groups, not individuals: outlook is better when the cancer is caught early and fully removed, and some people with advanced disease have done well for years on immunotherapy. After surgery, follow-up includes regular scans, because the cancer can return even after an apparently complete operation. People on immunotherapy or targeted drugs usually have treatment every few weeks, with blood tests and periodic scans to check whether it is working. Fatigue, breathlessness, pain and weight loss can affect daily life, and treatment side effects add to that burden. Palliative care, which focuses on relieving symptoms and supporting quality of life, can be offered alongside cancer treatment from the start, not only near the end of life. Help with breathing, pain, nutrition and emotional strain makes a real difference for many people and their families.

When to Seek Help

See a clinician if you have a cough that lasts or keeps getting worse, cough up blood, have chest pain, or lose weight without trying, especially if you smoke or used to smoke. These symptoms have many causes, but they deserve evaluation and often a chest scan. If you are being treated with immunotherapy, call your cancer care team right away about new or worsening cough, shortness of breath or chest pain, diarrhea or severe belly pain, yellowing of the skin or eyes, or unusual tiredness or headaches. These can be early signs of the immune system inflaming a healthy organ, and they are easier to treat when caught early, even if they start weeks after a dose.

Questions to Ask Your Doctor

  1. 1.Was the diagnosis made from a biopsy or from the whole removed tumor, and would a second pathology opinion be useful for a cancer this rare?
  2. 2.What stage is the cancer, and is surgery an option for me?
  3. 3.What did PD-L1 and genetic testing of my tumor show, and how do those results change my treatment choices?
  4. 4.What can I realistically expect from the recommended treatment, and are there clinical trials I could join?
  5. 5.How can palliative care and other support services help me now, alongside treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.